Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
BioStem Technologies, Inc. is a life sciences company committed to the research, creation, and production of pharmaceutical and regenerative medical treatments and services. The firm primarily develops diverse alternative biological products, largely derived from stem cells, aimed at addressing ailments such as joint pain, injuries to tendons and ligaments, as well as neurodegenerative and autoimmune conditions. Additionally, BioStem Technologies is involved in the repackaging and distribution of active pharmaceutical ingredients and other supplies essential for pharmaceutical compounding. The company also designs and sells nutraceutical products, including its proprietary lines like Dr. Dave's Best and Nesvik Organics, along with other non-branded items, distributing them across the United States and globally. Its sales operations predominantly leverage e-commerce platforms. Established in 2006, BioStem Technologies, Inc. maintains its operational base in Pompano Beach, Florida.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is undervalued on P/FCF.